Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Molecular Imaging and Biology

• Publication date

  2017-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11307-016-1019-9PMID 27798787
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.

  2014cited by this paper
• Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.

  2012cited by this paper
• Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.

  2012cited by this paper
• Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.

  2011cited by this paper
• Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of Nuclear Medicine Physicians and Radiation Oncologists

  2011cited by this paper
• Radioimmunotherapy in non-Hodgkin's lymphoma: Opinions of US medical oncologists and hematologists

  2010cited by this paper
• From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

  2009cited by this paper
• Circulating clonotypic B cells in classic Hodgkin lymphoma.

  2009cited by this paper
• Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma.

  2009cited by this paper
• A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3 + 3 Dose Escalation Scheme in Phase I Dose-Finding Studies

  2008cited by this paper
• 18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy

  2008cited by this paper
• Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice

  2007cited by this paper
• Revised response criteria for malignant lymphoma.

  2007cited by this paper
• Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.

  2007cited by this paper
• Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.

  2006cited by this paper
• Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.

  2005cited by this paper
• A case of post‐transplant lymphoproliferative disease presenting as CD20‐expressing, Epstein–Barr‐virus positive Hodgkin lymphoma

  2005cited by this paper
• Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.

  2005cited by this paper
• Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

  2005cited by this paper
• 131I-tositumomab therapy as initial treatment for follicular lymphoma.

  2005cited by this paper
• The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy

  2004cited by this paper
• Case of relapsed CD20(+) mixed‐cellularity Hodgkin disease treated with sequential rituximab and radiotherapy

  2004cited by this paper
• Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.

  2003cited by this paper
• A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

  2003cited by this paper
• Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

  2002cited by this paper
• Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

  2002cited by this paper
• Varied B‐cell immunophenotypes of Hodgkin/Reed–Sternberg cells in classic Hodgkin's disease

  2000cited by this paper
• Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma

  2000cited by this paper
• Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET.

  2000cited by this paper
• Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.

  2000cited by this paper
• Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin.

  1999cited by this paper
• Practical implementation of a modified continual reassessment method for dose-finding trials

  1998cited by this paper
• Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy.

  1997cited by this paper
• Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells.

  1997cited by this paper
• Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.

  1996cited by this paper
• Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody.

  1992cited by this paper
• Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

  1989cited by this paper

• Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.

  2021cites this paper
• Neurological Complications of Targeted Therapies and Immunotherapies for Cancer

  2021cites this paper
• Radioimmunotherapy Combined With Low-Intensity Ultrasound and Microbubbles: A Potential Novel Strategy for Treatment of Solid Tumors

  2021cites this paper
• Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials

  2021cites this paper
• Theranostics of Hematologic Disorders

  2021cites this paper
• Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns.

  2021cites this paper
• Early evaluation of tumor response to 90Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT?

  2019cites this paper
• Combination Radioimmunotherapy Strategies for Solid Tumors

  2019influential citation
• CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma

  2018cites this paper
• Dose individualization and variable selection by using the Bayesian lasso in early phase dose finding trials

  2018cites this paper
• Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives

  2017cites this paper
• Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis

  2017cites this paper